NCT00656825 - Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions

Healthy

Interventions

DRUG

P144 cream

P144 cream will be given at a dose of 100 μg/mL

DRUG

P144 cream

P144 cream will be given at a dose of 200 μg/mL

DRUG

P144 cream

P144 cream will be given at a dose of 300 μg/mL

DRUG

Placebo

Placebo will be randomly given to 4 subjects in each panel

Trial Locations (2)

Hospital Universitario Puerta de Hierro, Madrid

Clínica Universitaria de Navarra, Pamplona